AIM ImmunoTech (AIM) Competitors $2.60 +0.01 (+0.35%) As of 10:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AIM vs. SNPX, TLPH, AEON, OBSV, CYCN, NKGN, BIVI, GNPX, KPRX, and BCLIShould you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Synaptogenix (SNPX), Talphera (TLPH), AEON Biopharma (AEON), ObsEva (OBSV), Cyclerion Therapeutics (CYCN), NKGen Biotech (NKGN), BioVie (BIVI), GENPREX (GNPX), Kiora Pharmaceuticals (KPRX), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "pharmaceutical products" industry. AIM ImmunoTech vs. Its Competitors Synaptogenix Talphera AEON Biopharma ObsEva Cyclerion Therapeutics NKGen Biotech BioVie GENPREX Kiora Pharmaceuticals Brainstorm Cell Therapeutics AIM ImmunoTech (NYSE:AIM) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Which has more risk and volatility, AIM or SNPX? AIM ImmunoTech has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Do analysts prefer AIM or SNPX? AIM ImmunoTech presently has a consensus target price of $275.00, indicating a potential upside of 10,480.99%. Given AIM ImmunoTech's stronger consensus rating and higher probable upside, research analysts plainly believe AIM ImmunoTech is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, AIM or SNPX? Synaptogenix has lower revenue, but higher earnings than AIM ImmunoTech. Synaptogenix is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAIM ImmunoTech$146K13.60-$28.96M-$24.00-0.11SynaptogenixN/AN/A-$12.77M-$10.08-0.73 Do institutionals and insiders believe in AIM or SNPX? 12.0% of AIM ImmunoTech shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor AIM or SNPX? In the previous week, AIM ImmunoTech had 2 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for AIM ImmunoTech and 0 mentions for Synaptogenix. AIM ImmunoTech's average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score. Company Overall Sentiment AIM ImmunoTech Neutral Synaptogenix Neutral Is AIM or SNPX more profitable? Synaptogenix has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Synaptogenix's return on equity of -115.28% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets AIM ImmunoTech-12,594.21% -421.73% -147.54% Synaptogenix N/A -115.28%-58.31% SummarySynaptogenix beats AIM ImmunoTech on 8 of the 14 factors compared between the two stocks. Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIM vs. The Competition Export to ExcelMetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$2.00M$281.24M$5.49B$20.73BDividend YieldN/AN/A4.59%3.65%P/E Ratio-5.56N/A29.8928.12Price / Sales13.60509.72458.2757.77Price / CashN/A22.4424.8117.60Price / Book13.008.738.644.63Net Income-$28.96M-$115.81M$3.26B$994.60M7 Day Performance-10.99%-5.97%-0.02%0.37%1 Month Performance-71.67%-4.97%2.49%-0.63%1 Year Performance-90.23%-13.20%44.82%16.60% AIM ImmunoTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMAIM ImmunoTech1.163 of 5 stars$2.60+0.3%$275.00+10,481.0%-90.2%$2.00M$146K-5.5620SNPXSynaptogenixN/A$5.89-9.2%N/A+72.5%$8.19MN/A-0.584Upcoming EarningsTLPHTalphera2.6432 of 5 stars$0.40+1.3%$5.00+1,156.3%-57.9%$8.16M$650K-0.8819Negative NewsUpcoming EarningsAEONAEON Biopharma3.3867 of 5 stars$0.71-2.8%$360.00+50,320.2%-99.1%$8.07MN/A3.975OBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050CYCNCyclerion Therapeutics2.6925 of 5 stars$2.40-16.9%N/A-22.8%$7.77M$2M-2.0930Positive NewsEarnings ReportGap DownNKGNNKGen Biotech0.4803 of 5 stars$0.17+21.4%N/A-85.9%$7.64MN/A-0.03N/AGap UpBIVIBioVie0.3448 of 5 stars$4.06-18.1%N/A-92.8%$7.55MN/A-0.0510Gap UpHigh Trading VolumeGNPXGENPREX1.4833 of 5 stars$0.22-10.5%N/A-85.0%$7.36MN/A0.0020KPRXKiora Pharmaceuticals3.3801 of 5 stars$2.42-3.2%$10.00+313.2%-26.9%$7.36M$16.02M-0.8310Earnings ReportBCLIBrainstorm Cell Therapeutics1.7511 of 5 stars$0.63+8.6%N/A-84.6%$6.95MN/A-0.1940Upcoming Earnings Related Companies and Tools Related Companies SNPX Alternatives TLPH Alternatives AEON Alternatives OBSV Alternatives CYCN Alternatives NKGN Alternatives BIVI Alternatives GNPX Alternatives KPRX Alternatives BCLI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AIM) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access